Comparative Pharmacology
Head-to-head clinical analysis: CANAGLIFLOZIN versus JARDIANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANAGLIFLOZIN versus JARDIANCE.
CANAGLIFLOZIN vs JARDIANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Sodium-glucose co-transporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, lowering blood glucose independent of insulin.
100 mg orally once daily; may increase to 300 mg once daily for additional glycemic control.
10 mg orally once daily, may increase to 25 mg orally once daily if tolerated and additional glycemic control needed.
None Documented
None Documented
Terminal elimination half-life: 10.6–13.1 hours (single dose); steady-state: ~12.9 hours. Clinically, supports once-daily dosing with sustained SGLT2 inhibition over 24 hours.
Clinical Note
moderateCanagliflozin + Gatifloxacin
"Canagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateCanagliflozin + Rosoxacin
"Canagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateCanagliflozin + Levofloxacin
"Canagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateCanagliflozin + Trovafloxacin
"Canagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.9 hours in healthy subjects. Steady-state is achieved after 4-5 days of once-daily dosing. Effective half-life for accumulation: ~4-6 hours.
Renal: 33% (primarily tubular secretion, ~1% unchanged in urine; remainder as glucuronide metabolites); Fecal: 52% (as parent drug and metabolites); Biliary: minor (enterohepatic circulation suspected but not quantified).
Primarily renal: approximately 70-80% of absorbed dose excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal: ~10-20% via biliary and fecal elimination.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor